Search

Your search keyword '"Alifano, Marco"' showing total 13 results
Start Over Author "Alifano, Marco" Journal cancers
13 results on '"Alifano, Marco"'

3. External Validation of a Prognostic Score for Survival in Lung Carcinoids

Author

Chiappetta, Marco, primary, Tabacco, Diomira, additional, Sassorossi, Carolina, additional, Sperduti, Isabella, additional, Cusumano, Giacomo, additional, Terminella, Alberto, additional, Fournel, Ludovic, additional, Alifano, Marco, additional, Guerrera, Francesco, additional, Filosso, Pier Luigi, additional, Nicosia, Samanta, additional, Gallina, Filippo, additional, Facciolo, Francesco, additional, Margaritora, Stefano, additional, and Lococo, Filippo, additional

Published
2022
Full Text
View/download PDF

5. Enhanced Recovery Pathway in Lung Resection Surgery: Program Establishment and Results of a Cohort Study Encompassing 1243 Consecutive Patients

Author

Nguyen, Yen-Lan, primary, Maiolino, Elena, additional, De Pauw, Vincent, additional, Prieto, Mathilde, additional, Mazzella, Antonio, additional, Peretout, Jean-Baptiste, additional, Dechartres, Agnès, additional, Baillard, Christophe, additional, Bobbio, Antonio, additional, Daffré, Elisa, additional, and Alifano, Marco, additional

Published
2022
Full Text
View/download PDF

7. The Reality of Lung Cancer Paradox: The Impact of Body Mass Index on Long-Term Survival of Resected Lung Cancer. A French Nationwide Analysis from the Epithor Database

Author

Alifano, Marco, primary, Daffré, Elisa, additional, Iannelli, Antonio, additional, Brouchet, Laurent, additional, Falcoz, Pierre Emmanuel, additional, Le Pimpec Barthes, Françoise, additional, Bernard, Alain, additional, Pages, Pierre Benoit, additional, Thomas, Pascal Alexandre, additional, Dahan, Marcel, additional, and Porcher, Raphael, additional

Published
2021
Full Text
View/download PDF

8. How Phosphofructokinase-1 Promotes PI3K and YAP/TAZ in Cancer: Therapeutic Perspectives

Author

Philippe Icard, Alifano Marco, and Luca Simula

Subjects
Cancer Research, Oncology
Abstract

PI3K/AKT is one of the most frequently altered signaling pathways in human cancers, supporting the activation of many proteins sustaining cell metabolism, proliferation, and aggressiveness. Another important pathway frequently altered in cancer cells is the one regulating the YAP/TAZ transcriptional coactivators, which promote the expression of genes sustaining aerobic glycolysis (such as WNT, MYC, HIF-1), EMT, and drug resistance. Of note, the PI3K/AKT pathway can also regulate the YAP/TAZ one. Unfortunately, although PI3K and YAP inhibitors are currently tested in highly resistant cancers (both solid and hematologic ones), several resistance mechanisms may arise. Resistance mechanisms to PI3K inhibitors may involve the stimulation of alternative pathways (such as RAS, HER, IGFR/AKT), the inactivation of PTEN (the physiologic inhibitor of PI3K), and the expression of anti-apoptotic Bcl-xL and MCL1 proteins. Therefore, it is important to improve current therapeutic strategies to overcome these limitations. Here, we want to highlight how the glycolytic enzyme PFK1 (and its product F-1,6-BP) promotes the activation of both PI3K/AKT and YAP/TAZ pathways by several direct and indirect mechanisms. In turn, PI3K/AKT and YAP/TAZ can promote PFK1 activity and F-1,6-BP production in a positive feedback loop, thus sustaining the Warburg effect and drug resistance. Thus, we propose that the inhibition of PFK1 (and of its key activator PFK2/PFKFB3) could potentiate the sensitivity to PI3K and YAP inhibitors currently tested. Awaiting the development of non-toxic inhibitors of these enzymes, we propose to test the administration of citrate at a high dosage, because citrate is a physiologic inhibitor of both PFK1 and PFK2/PFKFB3. Consistently, in various cultured cancer cells (including melanoma, sarcoma, hematologic, and epithelial cancer cells), this “citrate strategy” efficiently inhibits the IGFR1/AKT pathway, promotes PTEN activity, reduces Bcl-xL and MCL1 expression, and increases sensitivity to standard chemotherapy. It also inhibits the development of sarcoma, pancreatic, mammary HER+ and lung RAS-driven tumors in mice without apparent toxicities.

Published
2022

10. Total Psoas Area and Total Muscular Parietal Area Affect Long-Term Survival of Patients Undergoing Pneumonectomy for Non-Small Cell Lung Cancer

Author

Daffrè, Elisa, primary, Prieto, Mathilde, additional, Martini, Katharina, additional, Hoang-Thi, Trieu-Nghi, additional, Halm, Nara, additional, Dermine, Hervè, additional, Bobbio, Antonio, additional, Chassagnon, Guillaume, additional, Revel, Marie Pierre, additional, and Alifano, Marco, additional

Published
2021
Full Text
View/download PDF

12. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Author

Tiako Meyo, Manuela, primary, Jouinot, Anne, additional, Giroux-Leprieur, Etienne, additional, Fabre, Elizabeth, additional, Wislez, Marie, additional, Alifano, Marco, additional, Leroy, Karen, additional, Boudou-Rouquette, Pascaline, additional, Tlemsani, Camille, additional, Khoudour, Nihel, additional, Arrondeau, Jennifer, additional, Thomas-Schoemann, Audrey, additional, Blons, Hélène, additional, Mansuet-Lupo, Audrey, additional, Damotte, Diane, additional, Vidal, Michel, additional, Goldwasser, François, additional, Alexandre, Jérôme, additional, and Blanchet, Benoit, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results